Leading the Way in Digital Health: Alex Therapeutics Welcomes Paul Kirchmeier as COO

September 1, 2023

Drawing from his background of successfully introducing and growing virtual care software and services, alongside managing decentralized trials, Paul enriches the capabilities of the Alex team and its partners.

Alex Therapeutics extends financing round to €4.75M with leading life science VC

March 3, 2023

Alex Therapeutics’ extends fundraising round to €4.75 million with major investment from Innovestor Life Science. Investing €1.25million, Innovestor joins impressive list top-tier life science and technology venture capital firms, including Hadean Ventures, Scale Capital, Sweet Capital (King founders), and Bonit Capital.

Alex Therapeutics & Vicore Pharma announce first patient enrolled in pivotal study for Almee™, a DTx anxiety therapy for pulmonary fibrosis patients

December 5, 2022

The pivotal study, investigating Alex Therapeutics’ and Vicore’s standalone digital therapy (DTx) treating anxiety in patients with pulmonary fibrosis (PF), has launched in the US. The randomized clinical investigation will evaluate the impact of dCBT-PF Almee™ in adult subjects with PF for 250 patients in a 9-week program.

Alex Therapeutics presents major Eila® clinical trial recruitment milestone

December 1, 2022

Alex Therapeutics, together with Pfizer, has reached the first major milestone in a clinical study of a digital therapeutic for the CBT-based treatment of tobacco dependence in Germany.

Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

October 13, 2022

Alex Therapeutics presents positive results from the pilot phase of a clinical study for one of their digital therapies treating anxiety in patients with the rare disease IPF. The primary objective of the study was to test the functionality, user experience, and safety of the DTx, which were all found to be positive. Additionally, using GAD-7, anxiety symptoms were shown to have been reduced by an average of 4.2 points, a 49% reduction.

Alex Therapeutics and Vicore Pharma launch clinical investigation of PF DTx

April 21, 2022

Clinical study investigating Alex Therapeutics’ and Vicore’s standalone digital therapy (DTx) treating anxiety in patients with pulmonary fibrosis (PF) has launched in the US. The clinical study consists of two phases; the current pilot study designed to refine the interactive nature of the therapy session, followed by a pivotal study.

Alex Therapeutics raises €3.5M from top VC investors

April 6, 2022

Alex Therapeutics raises €3.5M in oversubscribed financing round from top tier VC investors to advance expansion in Europe and the US. This funding round will be used to accelerate Alex's growth in Europe and the US and to develop novel DTx products alongside both new and existing partners, including Pfizer.

Pfizer and Alex Therapeutics announce Strategic Commercial Partnership

January 31, 2022

The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world-leading pharmaceutical company Pfizer have joined forces to provide evidence-based, clinically validated, and personalized digital therapies to patients. Together, the companies cover a broad range of expertise in the fields of medicine, marketing, clinical validation, AI, software development, and psychology. The partnership will initially focus on Germany, one of the world's largest unified healthcare markets.

Alex Therapeutics recieves Vinnova funding to develop tobacco cessation product in India

June 4, 2021

Alex Therapeutics has received approval and funding from Vinnova to develop, optimise and clinically validate an AI-based tobacco cessation treatment tailored to India. 

Alex Therapeutics partners with Pfizer Sweden in World No Tobacco Day campaign

May 31, 2021

Alex Therapeutics and the world leading pharmaceutical company Pfizer partner to combat the tobacco epidemic and help achieve a smoking-free society. Today, the 31st of May, is the World No Tobacco Day. Alex Therapeutics and Pfizer are seeking to draw attention to the continued global tobacco problem and as well as their collaboration to combat it. 

Vicore enters into collaboration with Alex Therapeutics to develop new prescription digital therapeutic for patients with IPF

May 4, 2021

Vicore Pharma, a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the signing of an agreement with Alex Therapeutics for the development of a clinically validated digital therapeutic (DTx) built on the “Alex DTx Platform”.

Alex Therapeutics receives funding from the King founders

July 23, 2018

Last year the billionaire entrepreneurs behind King.com founded the venture fund Sweet Studio. The fund, which manages roughly 100 million SEK in capital, has now made its first investment in Alex Therapeutics. 

Use the Alex DTx Platform to launch novel digital treatments

We partner with pharma, insurance and healthcare companies in developing and launching novel DTx treatments.

Get in touch